TY - JOUR
T1 - Long-term outcomes, quality of life, and costs of treatment modalities for T1–T2 lip carcinomas
AU - van Hof, Kira S.
AU - Wakkee, Marlies
AU - Sewnaik, Aniel
AU - Herkendaal, Aimée F.
AU - Tans, Lisa
AU - Mast, Hetty
AU - van den Bos, Renate R.
AU - Mureau, Marc A.M.
AU - Offerman, Marinella P.J.
AU - Baatenburg de Jong, Robert J.
N1 - Publisher Copyright:
© 2023 The Authors. Oral Diseases published by Wiley Periodicals LLC.
PY - 2024/5
Y1 - 2024/5
N2 - Purpose: Early stage lip squamous cell carcinoma (lip SCC) can be treated with conventional excision, Mohs micrographic surgery (MMS), or brachytherapy. The aim of this retrospective study was to describe the medical outcomes, patient-reported outcomes, and costs of these treatments. Methods: A retrospective cohort study of T1–T2 lip SSCs treated between 1996 and 2019. Medical outcomes, recurrences, and survival were retrieved from medical records. Facial appearance, facial function, and Quality of Life (QoL) were measured with the Face-Q H&N and EQ-5D-5L questionnaires. Costs were also calculated. Results: Of the 336 lip SCCs, 122 were treated with excision, 139 with MMS, and 75 with brachytherapy. Locally, the recurrence rate was 2.7% and regionally 4.8%. There were 2% disease-related deaths. T2-stage and poor tumor differentiation were associated with recurrences. Posttreatment QoL, facial function, and appearance were rated as good. Brachytherapy was the most expensive treatment modality. Conclusion: Early-stage lip SCC has a good prognosis, with a disease-specific survival of 98.2% after a median follow-up of 36 months, there was a high QoL and satisfaction at long-term follow-up. Based on the costs and the risk of locoregional recurrences, we believe that, for most noncomplex lip SCCs, MMS would be the most logical treatment option.
AB - Purpose: Early stage lip squamous cell carcinoma (lip SCC) can be treated with conventional excision, Mohs micrographic surgery (MMS), or brachytherapy. The aim of this retrospective study was to describe the medical outcomes, patient-reported outcomes, and costs of these treatments. Methods: A retrospective cohort study of T1–T2 lip SSCs treated between 1996 and 2019. Medical outcomes, recurrences, and survival were retrieved from medical records. Facial appearance, facial function, and Quality of Life (QoL) were measured with the Face-Q H&N and EQ-5D-5L questionnaires. Costs were also calculated. Results: Of the 336 lip SCCs, 122 were treated with excision, 139 with MMS, and 75 with brachytherapy. Locally, the recurrence rate was 2.7% and regionally 4.8%. There were 2% disease-related deaths. T2-stage and poor tumor differentiation were associated with recurrences. Posttreatment QoL, facial function, and appearance were rated as good. Brachytherapy was the most expensive treatment modality. Conclusion: Early-stage lip SCC has a good prognosis, with a disease-specific survival of 98.2% after a median follow-up of 36 months, there was a high QoL and satisfaction at long-term follow-up. Based on the costs and the risk of locoregional recurrences, we believe that, for most noncomplex lip SCCs, MMS would be the most logical treatment option.
UR - http://www.scopus.com/inward/record.url?scp=85169161833&partnerID=8YFLogxK
U2 - 10.1111/odi.14723
DO - 10.1111/odi.14723
M3 - Article
C2 - 37650356
AN - SCOPUS:85169161833
SN - 1354-523X
VL - 30
SP - 2063
EP - 2074
JO - Oral Diseases
JF - Oral Diseases
IS - 4
ER -